Compression of morbidity in a progeroid mouse model through the attenuation of myostatin/activin signalling

Show full item record



Permalink

http://hdl.handle.net/10138/312587

Citation

Alyodawi , K , Vermeij , W P , Omairi , S , Kretz , O , Hopkinson , M , Solagna , F , Joch , B , Brandt , R M C , Barnhoorn , S , van Vliet , N , Ridwan , Y , Essers , J , Mitchell , R , Morash , T , Pasternack , A , Ritvos , O , Matsakas , A , Collins-Hooper , H , Huber , T B , Hoeijmakers , J H J & Patel , K 2019 , ' Compression of morbidity in a progeroid mouse model through the attenuation of myostatin/activin signalling ' , Journal of cachexia, sarcopenia and muscle , vol. 10 , no. 3 , pp. 662-686 . https://doi.org/10.1002/jcsm.12404

Title: Compression of morbidity in a progeroid mouse model through the attenuation of myostatin/activin signalling
Author: Alyodawi, Khalid; Vermeij, Wilbert P.; Omairi, Saleh; Kretz, Oliver; Hopkinson, Mark; Solagna, Francesca; Joch, Barbara; Brandt, Renata M. C.; Barnhoorn, Sander; van Vliet, Nicole; Ridwan, Yanto; Essers, Jeroen; Mitchell, Robert; Morash, Taryn; Pasternack, Arja; Ritvos, Olli; Matsakas, Antonios; Collins-Hooper, Henry; Huber, Tobias B.; Hoeijmakers, Jan H. J.; Patel, Ketan
Contributor: University of Helsinki, Medicum
University of Helsinki, Department of Physiology
Date: 2019-06
Language: eng
Number of pages: 25
Belongs to series: Journal of cachexia, sarcopenia and muscle
ISSN: 2190-5991
URI: http://hdl.handle.net/10138/312587
Abstract: Background One of the principles underpinning our understanding of ageing is that DNA damage induces a stress response that shifts cellular resources from growth towards maintenance. A contrasting and seemingly irreconcilable view is that prompting growth of, for example, skeletal muscle confers systemic benefit. Methods To investigate the robustness of these axioms, we induced muscle growth in a murine progeroid model through the use of activin receptor IIB ligand trap that dampens myostatin/activin signalling. Progeric mice were then investigated for neurological and muscle function as well as cellular profiling of the muscle, kidney, liver, and bone. Results We show that muscle of Ercc1(Delta/-) progeroid mice undergoes severe wasting (decreases in hind limb muscle mass of 40-60% compared with normal mass), which is largely protected by attenuating myostatin/activin signalling using soluble activin receptor type IIB (sActRIIB) (increase of 30-62% compared with untreated progeric). sActRIIB-treated progeroid mice maintained muscle activity (distance travel per hour: 5.6 m in untreated mice vs. 13.7 m in treated) and increased specific force (19.3 mN/mg in untreated vs. 24.0 mN/mg in treated). sActRIIb treatment of progeroid mice also improved satellite cell function especially their ability to proliferate on their native substrate (2.5 cells per fibre in untreated progeroids vs. 5.4 in sActRIIB-treated progeroids after 72 h in culture). Besides direct protective effects on muscle, we show systemic improvements to other organs including the structure and function of the kidneys; there was a major decrease in the protein content in urine (albumin/creatinine of 4.9 sActRIIB treated vs. 15.7 in untreated), which is likely to be a result in the normalization of podocyte foot processes, which constitute the filtration apparatus (glomerular basement membrane thickness reduced from 224 to 177 nm following sActRIIB treatment). Treatment of the progeric mice with the activin ligand trap protected against the development of liver abnormalities including polyploidy (18.3% untreated vs. 8.1% treated) and osteoporosis (trabecular bone volume; 0.30 mm(3) in treated progeroid mice vs. 0.14 mm(3) in untreated mice, cortical bone volume; 0.30 mm(3) in treated progeroid mice vs. 0.22 mm(3) in untreated mice). The onset of neurological abnormalities was delayed (by similar to 5 weeks) and their severity reduced, overall sustaining health without affecting lifespan. Conclusions This study questions the notion that tissue growth and maintaining tissue function during ageing are incompatible mechanisms. It highlights the need for future investigations to assess the potential of therapies based on myostatin/activin blockade to compress morbidity and promote healthy ageing.
Subject: Compression
Morbidity
Progeroid
Ageing
Skeletal muscle
Myostatin
Liver
Kidney
Bone
Neurological
SKELETAL-MUSCLE
LIFE-SPAN
DNA-REPAIR
NUCLEAR ABNORMALITIES
MOLECULAR-MECHANISMS
CELL-PROLIFERATION
SATELLITE-CELL
GROWTH
MASS
HYPERTROPHY
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Alyodawi_et_al_ ... _Sarcopenia_and_Muscle.pdf 3.484Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record